Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

'New anti-flu drug will raise demand'

Tamiflu (oseltamivir), the anti-viral flu treatment launched last week, is expected to increase GP consultations from patients seeking the drug for themselves and from parents seeking it for their children, experts have warned.

Tamiflu is taken orally and, unlike Relenza (zanamivir), GPs can prescribe it to young children provided they are in an at-risk group and present within 48 hours of symptoms, according to guidance from the National Institute for Clinical Excellence.

Those considered 'at risk' include patients with any chronic respiratory disease, cardiovascular disease, chronic renal disease, diabetes mellitus or compromised immune systems, as well as all over-65s.

Professor John Oxford, professor of virology at Queen Mary University of London, said media publicity would raise awareness and demand.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say